G

GE Healthcare

Imaging, monitoring, and healthcare IT solutions

Indirect Contracting Team Leader - f/m/d, Pharmaceutical Diagnostics

Full-TimePosted on 10/8/2026Deadline 10/23/26
No salary listed
Mid
Remote in Germany
RemoteThe role may be performed remotely, hybrid, or onsite in any European country.
Contract Management

About the job

Requirements
  • Significant experience in contract drafting and management, commercial contracting, legal operations, public procurement, commercial operations, or a related field, preferably within healthcare, pharmaceutical, diagnostics, medical technology, or another regulated industry.
  • Strong understanding of contract lifecycle management, distributor or indirect customer contracting, compliance requirements, risk management, internal controls, and governance frameworks within regulated healthcare.
  • Proven ability to lead a team, set priorities, drive accountability, manage operational execution, and build team capability.
  • Demonstrated ability to lead process transformation, standardization, lean initiatives, Daily Management, continuous improvement, and operational excellence programs.
  • Strong analytical skills, including defining key performance indicators, creating performance transparency, interpreting operational data, identifying gaps, and driving improvement actions.
  • Strong stakeholder management, communication, and influencing skills, including aligning Compliance, Legal, Finance, Regulatory, Operations, Sales, and senior business stakeholders.
  • High attention to detail, strong organizational discipline, and commitment to quality, compliance, documentation accuracy, process adherence, and audit readiness.
  • Ability to operate with sound judgment, autonomy, and ownership within defined decision-making boundaries; manage competing priorities; resolve complex issues; and drive decisions across countries and functions.
  • Demonstrated experience operating across multiple jurisdictions, cultures, and regulatory environments in a global or regional organization.
  • Proven ability to lead organizational change, influence adoption of new processes, manage resistance, and sustain behavioral change across stakeholder groups.
  • Fluent English is required.
Responsibilities
  • Lead the end-to-end operational management of distributor, wholesaler, and sales representative contract lifecycles, including drafting, review, execution, renewal, amendment, extension, and termination.
  • Track and maintain contract coverage, expiry dates, status, renewal timelines, key obligations, the contract repository, and remediation actions in an accurate and audit-ready manner.
  • Identify indirect third parties operating without valid contract coverage and drive risk-based remediation, prioritizing expired or at-risk contracts.
  • Partner with Commercial, Compliance, Legal, Finance, and other stakeholders to manage customers without valid contract coverage according to controls, escalation pathways, ordering restrictions, and documentation requirements.
  • Enforce approved templates, complete due diligence and compliance reviews, and coordinate legal, regulatory, trade compliance, privacy, competition law, and anti-corruption assessments for third-party commercial contracts.
  • Escalate material risks, deviations, and approval requirements in accordance with company policies and applicable regulations.
  • Prioritize contract renewals and team workload, manage workflows, report governance information, escalate identified risks, and drive process improvements within relevant decision-making boundaries.
  • Lead, coach, and develop a team of contract specialists while ensuring clear priorities, high-quality execution, and consistent ways of working.
  • Set expectations for process adherence, documentation quality, stakeholder responsiveness, internal standards, and Daily Management.
  • Act as an escalation point for complex contracting topics, lapsed coverage, renewal prioritization, delays, deviations, and cross-functional alignment needs.
  • Train the team, build team capability, and foster accountability, ownership, collaboration, operational excellence, and continuous improvement.
  • Ensure indirect customer contracts comply with applicable laws, regulations, internal policies, standard operating procedures, approval requirements, and compliance standards.
  • Strengthen the contracting control environment through contract coverage, renewal governance, role clarity, process adherence, and risk escalation.
  • Define and maintain roles and responsibilities, including responsibility matrices for contract review, approval, renewal, escalation, and cross-functional decision-making.
  • Establish governance routines covering overdue actions, upcoming renewals, lapsed coverage, extensions, deviations, risks, process adherence, audit readiness, and remediation progress.
  • Support internal investigations, audit activities, compliance reviews, and management responses relating to indirect contracting activities.
  • Transform the indirect contracting process toward a standardized, lean, transparent, and controlled operating model.
  • Redesign the contract renewal lifecycle with initiation triggers, process maps, approval pathways, standard handoffs, defined ownership, mandatory function-specific review checkpoints, and deviation escalation.
  • Implement standard work, templates, process documentation, operating rhythms, and Daily Management across Pharmaceutical Diagnostics International.
  • Drive adoption of contract lifecycle management technologies, data quality standards, automation opportunities, and reporting capabilities.
  • Continuously improve routines to increase transparency, reduce email-based follow-up, improve action ownership, and reduce waste, waiting times, rework, and complexity.
  • Build and maintain a management system for indirect contracting, including key performance indicators, dashboards, performance reviews, action tracking, and governance routines.
  • Monitor contract lifecycle performance, including contracts executed before expiry, renewal cycle duration, extensions, lapsed coverage, overdue actions, deviations, backlog, and remediation progress.
  • Use data insights to identify bottlenecks, gaps, and process failures, and translate them into prioritization, escalation, resource allocation, and improvement actions.
  • Provide regular updates on performance, contract coverage, risks, remediation actions, efficiency improvements, and transformation milestones.
  • Build relationships with Compliance, Legal, Finance, Regulatory, Operations, Sales Managers, and regional leadership teams.
  • Align stakeholders on contracting priorities, process requirements, risk management expectations, roles and responsibilities, decision rights, and escalation points.
  • Communicate complex or sensitive contracting matters clearly and effectively to build consensus across functions.
  • Act as a senior point of contact for indirect contracting topics, escalations, governance discussions, remediation actions, and transformation initiatives.
Desired Qualifications
  • Experience managing distributor networks, working within regulated healthcare, leading cross-border contracting teams, implementing governance frameworks, and responding to internal or external audits.
  • Lean, project management, process excellence, workflow transformation, or contract lifecycle system experience.
  • Experience with contract workflows, contract lifecycles, and related information technology tools such as Salesforce.com.
  • Additional languages relevant to Pharmaceutical Diagnostics International.

About the company

GE Healthcare Systems provides medical technologies and digital infrastructure to improve diagnosis, treatment, and monitoring of patients. Its products include imaging systems, mobile diagnostic devices, patient monitoring tools, and healthcare IT software that work together as hardware, software, and services to support hospitals, clinics, and researchers. The company differentiates itself with a large, integrated ecosystem, strong focus on AI analytics, and a global service network backed by substantial R&D investment. Its goal is to improve patient outcomes and the efficiency of healthcare delivery by enabling accurate diagnoses, effective treatments, and scaled operations.

Company Size

1-10

Company Stage

IPO

Headquarters

Chicago, Illinois

Founded

1892

Get referred to GE Healthcare

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 orders rose 11% and backlog reached a record $23.9 billion.
  • CareIntellect for Operations launched September 2026 with Duke Health and Queen's Health Systems.
  • CE mark and FDA progress for Photonova Spectra expand 2026-2027 commercial momentum.

What critics are saying

  • FDA logged multiple 2026 Class 2 recalls, including AW Server and telemetry systems.
  • Patient Care Solutions remained weak in Q2 2026; management is reviewing a sale.
  • SOFIE closes only after 2027 regulatory approvals; PET supply integration can slip badly.

What makes GE Healthcare unique

  • GE HealthCare combines imaging hardware, radiopharmaceuticals, and workflow software across hospitals.
  • Photonova Spectra and Vivid 2026 show premium innovation plus AI-enabled clinical automation.
  • SOFIE's 21 cyclotrons extend GE HealthCare into radiotracer manufacturing, not just scanners.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Tuition Reimbursement
  • Relocation Assistance

Company News

Associated Press
Oct 20th, 2026
GE HealthCare launches five-institution global trial of StarGuide GX theranostics SPECT/CT system

GE HealthCare has launched a clinical evaluation program for StarGuide GX, its next-generation digital 4D SPECT/CT system. Five institutions across three continents will take part. They are Hadassah Medical Center and Rambam Health Care Campus in Israel, Mayo Clinic in the US, Oncopole Claudius Regaud in France, and Peking University First Hospital in China. Each will assess image quality, quantitative performance, dynamic imaging, and workflow, and give feedback to guide the system's development. StarGuide GX uses dual-sided cadmium zinc telluride detectors and a dual-collimator design meant to remove manual collimator changes. It also uses NVIDIA RTX accelerated computing for image reconstruction. The system received CE Mark in November 2025 and is on sale in select EU states. Its US Food and Drug Administration 510(k) clearance is pending.

Yahoo Finance
Oct 19th, 2026
GE HealthCare launches LOGIQ Focus ultrasound with AI tools, 26% faster scans

GE HealthCare has launched LOGIQ Focus, a new general imaging ultrasound system in its LOGIQ family. The company announced the product in Chicago on October 19, 2026. The system runs on cSound Architecture and pairs high-definition imaging with AI-enabled tools. One of them, Auto Preset Assistant, detects the anatomy being scanned and activates the matching preset, saving up to five clicks per exam. In a third-party study, 90% of participants rated its image quality as excellent. The system was 26% faster than the predicate system. LOGIQ Focus is 510(k) cleared and CE Marked. GE HealthCare expects it and several other new products to add 1% to 2% to revenue growth, following more than $5 billion in innovation investment since 2023.

Business Wire
Oct 5th, 2026
GE HealthCare to acquire SOFIE Biosciences for $945M to expand US radiopharmaceutical supply

GE HealthCare has agreed to acquire SOFIE Biosciences, a US-based contract manufacturer of PET radiopharmaceuticals, for $945 million in cash. The deal with seller Trilantic North America is expected to close in the first half of 2027, subject to regulatory approvals. SOFIE Biosciences operates 15 contract manufacturing sites with 21 cyclotrons across the US, plus a theranostics-focused development and manufacturing facility. The acquisition establishes GE HealthCare's presence in the time-critical "final mile" of US PET radiopharmaceutical supply. The PET radiopharmaceutical market is expanding rapidly with approximately 20 PET radiotracers and over 30 radiotherapeutics currently under development. SOFIE Biosciences' portfolio includes a Phase III FAPI asset for which GE HealthCare already holds non-US rights. GE HealthCare estimates the transaction will be accretive to revenue growth, earnings margin, and earnings per share in the first full year of ownership.

PR Newswire
Sep 30th, 2026
AsiaMedic first in ASEAN to deploy GE HealthCare's MR31 deep learning MRI platform

AsiaMedic has become the first site in ASEAN to implement MR31, GE HealthCare's latest generation MRI platform featuring deep learning technology. The Singapore-based imaging centre is among the earliest adopters in Asia Pacific. MR31 incorporates deep learning technologies that reduce scan times and enable detailed examinations across neurological, musculoskeletal and nerve imaging. Sonic DL for 3D delivers up to 12 times scan acceleration, reducing examination times across brain, spine, orthopaedic and body scans. The platform also supports high-quality prostate MRI imaging. AIR Recon DL Phase Correction provides improved visualisation of clinically significant lesions, whilst high-resolution T2-weighted imaging aids lesion localisation for prostate fusion biopsy planning. Shorter scan times mean reduced patient time in scanners and may help decrease repeat examinations caused by movement.

Associated Press
Sep 22nd, 2026
GE HealthCare raises quarterly dividend 14% to $0.04 per share for Q3 2026

GE HealthCare Technologies announced a 14% dividend increase for the third quarter of 2026. The company's board declared a cash dividend of $0.04 per share, up from the previous quarter. The dividend will be paid on 13 November 2026 to shareholders of record as of 23 October 2026. GE HealthCare is a global healthcare solutions provider specialising in medical technology, pharmaceutical diagnostics, and AI-enabled software solutions. The company operates a $20.6 billion business with approximately 54,000 employees worldwide, serving the healthcare industry through its Advanced Imaging Solutions, Pharmaceutical Diagnostics, and Patient Care Solutions segments.

INACTIVE